Bender Robert & Associates’s AstraZeneca AZN Stock Holding History

Bender Robert & Associates’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-6,101	Closed	-$799K	–	41
2024 Q4	$799K	Sell	6,101 -840	-12%	-$118K	0.19%	28
2024 Q3	$1.08M	Buy	+6,941	New	+$1.12M	0.23%	27
2024 Q2	–	Sell	-9,407	Closed	-$1.42M	–	48
2024 Q1	$1.27M	Sell	9,407 -2,182	-19%	-$289K	0.3%	28
2023 Q4	$1.56M	Sell	11,589 -2,721	-19%	-$354K	0.39%	26
2023 Q3	$1.94M	Sell	14,310 -1,488	-9%	-$203K	0.57%	25
2023 Q2	$2.26M	Sell	15,798 -6,332	-29%	-$932K	0.62%	25
2023 Q1	$3.07M	Buy	22,130 +15	+0.1%	+$2.02K	0.95%	22
2022 Q4	$3M	Sell	22,115 -1,093	-5%	-$137K	1.12%	23
2022 Q3	$2.54M	Buy	23,208 +481	+2%	+$61K	0.99%	24
2022 Q2	$3M	Sell	22,727 -442	-2%	-$58K	1.15%	24
2022 Q1	$3.07M	Sell	23,169 -121	-0.5%	-$14.5K	0.88%	23
2021 Q4	$2.8M	Hold	23,290	–	–	0.81%	25
2021 Q3	$2.8M	Buy	+23,290	New	+$2.71M	0.8%	25

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

Bender Robert & Associates's AZN Position: Q1 2025 in Review

Bender Robert & Associates sold out of AstraZeneca (AZN) in Q1 2025, closing a stake of 6,101 shares — an estimated $799K sold.

Bender Robert & Associates first reported a position in AZN in Q3 2021 and held it in 13 quarters. The position peaked at $3.07M in Q1 2022. 1,250 funds tracked by Wall St. Rank hold AZN as of Q1 2025.

Bender Robert & Associates reported no remaining AstraZeneca position as of Q1 2025 after selling out during the quarter.
Bender Robert & Associates sold 6,101 AstraZeneca shares in Q1 2025, an estimated $799K.
Bender Robert & Associates first reported a position in AstraZeneca in Q3 2021 and held it in 13 quarters.
Bender Robert & Associates's AstraZeneca position peaked at $3.07M in Q1 2022.
1,250 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2025.

Based on Bender Robert & Associates's 13F filing for Q1 2025, filed 18 Apr 2025.